Eye disease biotech Aerie Pharmaceuticals files for a $58 million IPO
Aerie Pharmaceuticals, a clinical-stage biotech developing treatments for glaucoma and other eye diseases, filed on Tuesday with the SEC to raise up to $58 million in an initial public offering. The Bedminster, NJ-based company, which was founded in 2005, plans to list on the NASDAQ under the symbol AERI. Aerie Pharmaceuticals initially filed confidentially on May 13, 2013. RBC Capital Markets and Stifel are the joint bookrunners on the deal. No pricing terms were disclosed.